Alexandre R Zlotta

Summary

Affiliation: Mount Sinai Hospital
Country: Canada

Publications

  1. pmc Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
    Sultan S Alkhateeb
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Urol Ann 3:119-26. 2011
  2. pmc Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy
    Mischel G Neill
    Division of Urology, Department of Surgical Oncology, Princess Margaret and Mount Sinai Hospitals, University of Toronto Toronto, Canada
    Ther Clin Risk Manag 4:11-8. 2008
  3. ncbi request reprint Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men
    Alexandre R Zlotta
    Department of Surgery, Division of Urology, University of Toronto, Mount Sinai Hospital, Toronto, ON, M5T 3L9, Canada
    J Natl Cancer Inst 105:1050-8. 2013
  4. doi request reprint Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer
    Alexandre R Zlotta
    Division of Urology, Mount Sinai Hospital, Toronto, Canada
    Eur Urol 59:1026-31. 2011
  5. ncbi request reprint Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors
    Sultan S Alkhateeb
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Urol 184:81-6. 2010
  6. doi request reprint Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols
    Nathan Perlis
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, M5G 2M9, Canada
    World J Urol 31:161-7. 2013
  7. doi request reprint A new and highly prognostic system to discern T1 bladder cancer substage
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, Canada
    Eur Urol 61:378-84. 2012
  8. doi request reprint Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment
    David M Kakiashvili
    Department of Surgical Oncology Division of Urology, Princess Margaret Hospital, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    BJU Int 107:540-6. 2011
  9. ncbi request reprint Pathological stage review is indicated in primary pT1 bladder cancer
    Bas W G van Rhijn
    Department of Surgical Oncology, Mount Sinai Hospital, Toronto, Canada
    BJU Int 106:206-11. 2010
  10. doi request reprint Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
    BJU Int 110:1169-76. 2012

Collaborators

Detail Information

Publications35

  1. pmc Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
    Sultan S Alkhateeb
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Urol Ann 3:119-26. 2011
    ....
  2. pmc Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy
    Mischel G Neill
    Division of Urology, Department of Surgical Oncology, Princess Margaret and Mount Sinai Hospitals, University of Toronto Toronto, Canada
    Ther Clin Risk Manag 4:11-8. 2008
    ....
  3. ncbi request reprint Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men
    Alexandre R Zlotta
    Department of Surgery, Division of Urology, University of Toronto, Mount Sinai Hospital, Toronto, ON, M5T 3L9, Canada
    J Natl Cancer Inst 105:1050-8. 2013
    ..We prospectively compared PCa prevalence in CAU and ASI men from specific populations with low penetrance of prostate-specific antigen screening...
  4. doi request reprint Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer
    Alexandre R Zlotta
    Division of Urology, Mount Sinai Hospital, Toronto, Canada
    Eur Urol 59:1026-31. 2011
    ..Screening is unproven to enable the detection of more non-muscle-invasive tumors. BC association with aristolochic acid nephropathy (AAN) was reported after intake of slimming pills containing Chinese herbs...
  5. ncbi request reprint Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors
    Sultan S Alkhateeb
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Urol 184:81-6. 2010
    ..We examined this issue by comparing the prognosis of primary vs nonprimary T1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin...
  6. doi request reprint Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols
    Nathan Perlis
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, M5G 2M9, Canada
    World J Urol 31:161-7. 2013
    ..Secondary objective is to evaluate whether or not recurrence patterns are similar between two centres with different post-RC follow-up (F/U) protocols...
  7. doi request reprint A new and highly prognostic system to discern T1 bladder cancer substage
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, Canada
    Eur Urol 61:378-84. 2012
    ..Management of T1 bladder cancer (BCa) is controversial...
  8. doi request reprint Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment
    David M Kakiashvili
    Department of Surgical Oncology Division of Urology, Princess Margaret Hospital, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    BJU Int 107:540-6. 2011
    ..To report the long-term results of bacille Calmette-Guérin (BCG) intravesical therapy in relation to disease progression and recurrence in primary T1 high-grade (HG) bladder cancer (BC) confirmed by central pathological review...
  9. ncbi request reprint Pathological stage review is indicated in primary pT1 bladder cancer
    Bas W G van Rhijn
    Department of Surgical Oncology, Mount Sinai Hospital, Toronto, Canada
    BJU Int 106:206-11. 2010
    ..To evaluate the effect of a pathology review on the clinical outcome of patients with primary pT1 bladder cancer (BC), as the clinical course of such patients is variable...
  10. doi request reprint Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
    BJU Int 110:1169-76. 2012
    ..Future studies may lead to the incorporation of sub-stage (T1m/T1e) in the TNM classification system for urinary BC to guide clinical decision-making in T1 BC...
  11. doi request reprint Does patient age affect survival after radical cystectomy?
    David Horovitz
    Department of Surgical Oncology, Division of Urology, University of Toronto, Princess Margaret Hospital, Toronto, Canada
    BJU Int 110:E486-93. 2012
    ..Pathological specimens were reviewed by dedicated genitourinary pathologists, including those recovered from peripheral hospitals. Our sample size is one of the largest single- or multi-institutional studies...
  12. ncbi request reprint Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
    Polat Türker
    Department of Surgical Oncology, Division of Urology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
    BJU Int 110:804-11. 2012
    ..Identification of patients at high risk of upstaging at radical cystectomy is key to improving their management and outcome...
  13. doi request reprint Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer
    Antonio Finelli
    Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada
    Eur Urol 59:509-14. 2011
    ..In two large randomized controlled trials, 5α-reductase inhibitors (5-ARIs) were shown to prevent prostate cancer. No prior work had shown the effect of 5-ARIs on those already diagnosed with low-risk prostate cancer...
  14. doi request reprint Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
    Greg Trottier
    Princess Margaret Hospital, University of Toronto, Toronto, Canada
    BJU Int 108:E237-44. 2011
    ..To compare the Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) and European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC) in a single-institution Canadian cohort...
  15. doi request reprint The FGFR3 mutation is related to favorable pT1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 187:310-4. 2012
    ..We determined the frequency of FGFR3 mutations and P53 alterations in patients with pT1 bladder cancer and correlated these data to histopathological variables and clinical outcomes...
  16. doi request reprint Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study
    Carmen Mir
    Division of Urology, Mount Sinai Hospital, Rochester, NY, USA
    BJU Int 108:24-30. 2011
    ..To investigate androgen receptor (AR) expression in a large series of patients with bladder cancer (BC) because data on a limited number of patients showed that loss of AR expression was associated with invasive BC...
  17. doi request reprint Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review
    Nathan Perlis
    University Health Network, Toronto, Ontario, Canada
    Eur Urol 64:421-30. 2013
    ..A meta-analysis of seven trials published in 2004 demonstrated that intravesical chemotherapy (IVC) following TURBT reduces recurrences. Despite European Association of Urology endorsement, adoption of this practice has been modest...
  18. doi request reprint Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma
    Michelle R Downes
    Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada
    J Clin Pathol 66:779-86. 2013
    ..Androgen receptor (AR) expression is maintained in high-grade, undifferentiated prostate carcinoma, and thus, could be considered as a potentially useful adjunct to the conventional panel of markers...
  19. doi request reprint Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer
    Peter J Bostrom
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    BJU Int 109:70-6. 2012
    ..To study the effect of smoking on bladder cancer presentation and outcome in a large cystectomy population...
  20. ncbi request reprint Lean methodology improves efficiency in outpatient academic uro-oncology clinics
    Sean C Skeldon
    Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada Electronic address
    Urology 83:992-7. 2014
    ..To determine if lean methodology, an industrial engineering tool developed to optimize manufacturing efficiency, can successfully be applied to improve efficiencies and quality of care in a hospital-based high-volume uro-oncology clinic...
  21. doi request reprint Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection
    Abdullah M Al-Ghamdi
    University Health Network, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 179:1332-4. 2008
    ..A basic tenet of measurement theory is that repeat measurement improves validity. We determined whether an extended pattern prostate biopsy technique could overcome this bias...
  22. ncbi request reprint Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology
    Theodorus H van der Kwast
    Department of Pathology and Laboratory Medicine, University Health Network and Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Anal Quant Cytol Histol 30:309-15. 2008
    ..To harmonize nomenclature, we now propose that the terms low and high grade papillary urothelial carcinoma be replaced by low and high grade papillary intraurothelial neoplasiafor all noninvasive urothelial cancers...
  23. ncbi request reprint Strategies to preserve prostate health
    Mischel G Neill
    Department of Urologic Oncology, Princess Margaret and Mount Sinai Hospitals, University of Toronto, Toronto, Canada
    Drugs Today (Barc) 45:63-80. 2009
    ....
  24. doi request reprint Optimal timing of radical cystectomy in T1 high-grade bladder cancer
    Peter J Bostrom
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Expert Rev Anticancer Ther 10:1891-902. 2010
    ....
  25. ncbi request reprint Pharmacotherapy for prostate cancer: the role of hormonal treatment
    Rohan Shahani
    Division of Urology, Murray Koffler Urologic Wellness Centre, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Discov Med 7:118-24. 2007
    ..We explore the evidence, controversies and future of androgen deprivation therapy and critically reexamine the dogmas surrounding hormone therapy for prostate cancer...
  26. doi request reprint The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride
    Mireia Musquera
    University Clinics of Barcelona, c o Alexandre R Zlotta, Mount Sinai Hospital, Joseph and Wolf Lebovic Building, 60 Murray Street, 6th Floor, Box 19, Toronto, Ontario M5T 3L9, Canada
    Expert Rev Anticancer Ther 8:1073-9. 2008
    ..As a result, dutasteride is being investigated for prostate cancer prevention in the ongoing Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, which is discussed here...
  27. pmc Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?
    Sultan Saud Alkhateeb
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    Urol Ann 2:58-62. 2010
    ..We examined the relationship of NSRP with PSM and BP using a large, mature dataset...
  28. pmc Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer
    Ekaterina Olkhov-Mitsel
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Epigenetics 7:1037-45. 2012
    ..A similar trend for KLK6 DNA methylation was observed. The results suggest that KLK6 and KLK10 DNA methylation distinguishes organ confined from locally invasive PCa and may have prognostic value...
  29. pmc The management of BCG failure in non-muscle-invasive bladder cancer: an update
    Alexandre R Zlotta
    Department of Surgery, Division of Urology, University of Toronto
    Can Urol Assoc J 3:S199-205. 2009
    ..In this review, reasons explaining BCG failure, how to define BCG failure, optimal risk stratification and prediction of response and management of BCG failures are discussed...
  30. doi request reprint BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer
    Alexandre R Zlotta
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital and the University Health Network, Mt Sinai Hospital, University of Toronto, Ontario, Canada
    Urol Oncol 28:329-33. 2010
    ..Given the costs associated with the treatment and surveillance of bladder cancer, a comprehensive program supported by governmental funding sources to identify the risks associated with bladder cancer development would seem prudent...
  31. doi request reprint The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma
    Michael Ordon
    Department of Pathology, University Health Network, Toronto, Canada
    BJU Int 104:1641-5. 2009
    ....
  32. ncbi request reprint Prostate cancer prevention: past, present, and future
    Neil Fleshner
    Division of Urology, University Health Network, and Department of Surgery Urology, University of Toronto, Toronto, Ontario, Canada
    Cancer 110:1889-99. 2007
    ..Probably no cancer is being investigated more thoroughly in the context of prevention as prostate cancer in 2007. Definitive answers to pivotal phase 3 trials will be available in the coming 2 to 7 years...
  33. doi request reprint Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer
    Sean C Skeldon
    Department of Surgical Oncology, Urology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Eur Urol 63:379-85. 2013
    ..An increased risk for upper tract urothelial carcinoma (UTUC) has been described in this population; however, data regarding the risk for bladder cancer (BCa) are sparse...
  34. doi request reprint Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University of Toronto, UHN, Toronto, Ontario, Canada
    Eur Urol 56:430-42. 2009
    ..This review focuses on the prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease...
  35. pmc Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records
    Peter J Bostrom
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Am Med Inform Assoc 18:835-41. 2011
    ..The use of a human factors laboratory to study management of disease using simulated clinical scenarios was also assessed...